WallStSmart
OKUR

OnKure Therapeutics, Inc.

NASDAQ: OKUR · HEALTHCARE · BIOTECHNOLOGY

$4.28
-4.04% today

Updated 2026-07-10

Market cap
$184.20M
P/E ratio
P/S ratio
EPS (TTM)
$-4.32
Dividend yield
52W range
$2 – $5
Volume
0.3M

OnKure Therapeutics, Inc. (OKUR) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212022202320242025
Total assets$55.22M$154.02M$16.00M$35.73M$114.91M$62.12M
Cash & equivalents$53.61M$124.66M$11.54M$29.88M$110.76M$59.05M
Current assets$55.02M$153.73M$13.62M$33.77M$113.00M$60.84M
Total liabilities$97.34M$6.81M$70.42M$137.58M$11.08M$5.93M
Current liabilities$4.58M$6.20M$5.54M$7.29M$10.53M$5.92M
Long-term debt
Shareholder equity$-42.12M$147.21M$-54.42M$-101.84M$103.83M$56.18M
Retained earnings$-44.96M$-84.73M$-57.07M$-102.05M$-154.72M$-214.24M
Accounts receivable
Inventory
Goodwill

Frequently asked questions

How much free cash flow does OKUR generate?

OKUR produced $-51.87M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is OKUR's balance sheet healthy?

OKUR holds $59.05M in cash and equivalents against — in long-term debt, on $56.18M of shareholder equity. That debt is best read against the cash flow the business throws off each year.